Scarica l'app Stockscreener
2.79
7.31%
-0.22
Dopo l'orario di chiusura:
2.79
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$3.01
Aprire:
$2.91
Volume 24 ore:
2.49M
Relative Volume:
1.89
Capitalizzazione di mercato:
$451.83M
Reddito:
-
Utile/perdita netta:
$-274.18M
Rapporto P/E:
-1.1008
EPS:
-2.5346
Flusso di cassa netto:
$-198.33M
1 W Prestazione:
+7.72%
1M Prestazione:
+52.46%
6M Prestazione:
+259.44%
1 anno Prestazione:
-76.17%
Intervallo 1D:
$2.7201
$2.955
Intervallo di 1 settimana:
$2.40
$3.25
Portata 52W:
$0.611
$14.09
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Confronta NMRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.79 | 487.46M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Neumora Therapeutics Inc. stock outlook for YEARStock Surge & Stock Portfolio Risk Control - newser.com
Can Neumora Therapeutics Inc. stock maintain growth trajectoryTake Profit & Risk Adjusted Buy/Sell Alerts - newser.com
Heatmap analysis for Neumora Therapeutics Inc. and competitors2025 Price Action Summary & Long-Term Growth Plans - newser.com
How moving averages guide Neumora Therapeutics Inc. tradingPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Neumora Therapeutics accelerates investor outreach in Boston and New York - Traders Union
Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times
Real time social sentiment graph for Neumora Therapeutics Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
Neumora (Nasdaq: NMRA) to participate in two November conferences; webcasts available - Stock Titan
Why Neumora Therapeutics Inc. stock is a must watch in 20252025 Valuation Update & Growth-Oriented Investment Plans - newser.com
Can a trend reversal in Neumora Therapeutics Inc. lead to recoveryPortfolio Performance Report & Daily Volume Surge Signals - newser.com
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
What risks investors should watch in Neumora Therapeutics Inc. stockEarnings Overview Report & Daily Technical Stock Forecast Reports - newser.com
Neumora Therapeutics, Inc. (NMRA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Is Neumora Therapeutics Inc. stock entering bullish territoryJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
Will Neumora Therapeutics’ (NMRA) Novel Drug Pipeline Define Its Competitive Edge in Biotech? - Sahm
What momentum shifts mean for Neumora Therapeutics Inc.July 2025 WrapUp & Expert Curated Trade Setup Alerts - newser.com
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies - MSN
Regression analysis insights on Neumora Therapeutics Inc. performance2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Published on: 2025-10-31 04:44:03 - newser.com
Published on: 2025-10-31 03:53:08 - newser.com
Neumora Therapeutics, Inc. (NMRA) stock price, news, quote and history - Yahoo! Finance UK
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Insider Monkey
Arch Venture Partners Xii, Llc Acquires 1,915,700 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Director Kristina Burow Acquires 1,915,700 Shares - MarketBeat
Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder - MSN
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Game-Changer for Depression Treatment - MSN
Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy - The Globe and Mail
Neumora Therapeutics Advances MDD Treatment with Long-term Study - MSN
Neumora to initiate phase 1 study of oral obesity pill - MSN
Neumora Therapeutics Insider Bought Shares Worth $4,999,977, According to a Recent SEC Filing - MarketScreener
Neumora Therapeutics price target raised to $8 from $6 at Needham - MSN
Published on: 2025-10-30 01:21:45 - newser.com
Major Stakeholders Make Bold Moves in Neumora Therapeutics! - TipRanks
[Form 4] Neumora Therapeutics, Inc. Insider Trading Activity - Stock Titan
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $8.00 - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Neumora Therapeutics Inc. stock a top pick in earnings season2025 Buyback Activity & Safe Entry Zone Tips - fcp.pa.gov.br
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment - MSN
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):